A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2017 Planned End Date changed from 1 Jun 2018 to 8 Sep 2018.
- 07 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 8 Sep 2017.